Methotrexate Treatment Suppresses Monocytes in Nonresponders to Pneumococcal Conjugate Vaccine in Rheumatoid Arthritis Patients

Table 2

Frequencies of circulating leukocytes in RA patients and HC, at baseline.

Phenotype (% of leukocytes unless otherwise specified)	Healthy controls ()	RA 0DMARD ()	RA MTX ()
Monocytes	5.62 (4.82-7.58)	5.88 (5.04-8.56)	6.34 (5.03-7.47)
CD14^++CD16^- (% of monocytes)	84.5 (79.3-87.8)	86.2 (81.9-91.0)	86.6 (83.7-90.9)
CD14^++CD16^+ (% of monocytes)	2.62 (2.04-4.14)	4.77 (2.24-5.55)	4.12 (1.78-4.70)
CD14^+CD16^++ (% of monocytes)	13.3 (9.11-16.0)	9.21 (5.41-12.6)	8.63 (5.58-12.9)
Granulocytes	60.1 (43.5-69.6)	66.0 (57.4-82.0)	66.3 (58.3-79.7)
Basophils	0.940 (0.570-1.24)	0.885 (0.433-1.10)	1.04 (0.670-1.26)
Eosinophils	3.00 (1.60-3.29)	1.71 (0.938-4.69)	2.76 (2.13-5.32)
Neutrophils	57.9 (39.2-66.1)	59.4 (55.7-79.0)	60.8 (53.1-76.2)
Lymphocytes	24.8 (20.9-42.0)	20.1 (9.00-32.4)	19.2 (11.6-27.1)

Frequencies of circulating monocytes, granulocytes, and lymphocytes analyzed in patients with RA (in the MTX group before scheduled MTX treatment) and healthy controls, before administration of PCV13, using flow cytometry. Kruskal-Wallis test and Dunn’s multiple comparisons test were used to calculate level of significance. There were no statistical differences in frequencies between the three groups. Data are presented with medians and interquartile ranges. RA: rheumatoid arthritis; HC: healthy control, 0DMARD: without disease-modifying antirheumatic drug treatment; MTX: methotrexate.